Login / Signup

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.

Chiao-En WuChan-Keng YangMeng-Ting PengPei-Wei HuangChing-Fu ChangKun-Yun YehChun-Bing ChenChih-Liang WangChao-Wei HsuI-Wen ChenCheng-Tao LinShir-Hwa UengGigin LinYu-Fen LinChi-Yuan ChengJohn Wen-Cheng Chang
Published in: BMC cancer (2020)
Melanoma patients undergoing anti-PD-1 monotherapy and experiencing mild-to-moderate irAEs (grade 1-2), particularly skin (vitiligo)/endocrine irAEs had favorable survival outcomes. Therefore, the association between irAEs and the clinical outcomes in melanoma patients undergoing anti-PD-1 ICIs may be severity and type dependent.
Keyphrases
  • patients undergoing
  • skin cancer
  • basal cell carcinoma
  • open label
  • clinical trial
  • soft tissue
  • combination therapy
  • wound healing